Aryldihydronaphtalene-type lignans from Bursera fagaroides var. fagaroides and their antimitotic mechanism of action

Mayra Y. Antúnez Mojica^a, Alejandra León^a, Andrés M. Rojas-Sepúlveda^b, Silvia Marquina^a, Mario A. Mendieta-Serrano^c, Enrique Salas-Vidal^{c,*}, María Luisa Villarreal^d, Laura Alvarez^{a,*}

^aCentro de Investigaciones Químicas-IICBA, and ^dCentro de Investigación en Biotecnología, Universidad Autónoma del Estado de Morelos, Avenida Universidad 1001, Chamilpa, Cuernavaca, Morelos 62209, México. ^bFacultad de Ciencias, Universidad Antonio Nariño, Armenia, Quindío, Colombia. ^cDepartamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, A.P. 510-3, Cuernavaca, Morelos 62271, México.

Corresponding autors

Laura Alvarez

Centro de Investigaciones Químicas-IICBA, Universidad Autónoma del Estado de Morelos. Av. Universidad 1001, Col. Chamilpa, Cuernavaca, Morelos 62209, México

lalvarez@uaem.mx

Phone: +52 777 3297997; +52 777 3079200

Enrique Salas Vidal

Departamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, A.P. 510-3, Cuernavaca, Morelos 62271, México.

esalas@ibt.unam.mx

Phone: +52 7773291663; Fax: +52 777 3172388

List of Figures

- Figure S.1.1 ¹H NMR spectrum of compound 1 (400 MHz, CDCl₃)
- Figure S.1.2. ¹³C NMR spectrum of compound 1 (100 MHz, CDCl₃)
- Figure S.1.3. HSQC spectrum of compound 1 (CDCl₃)
- Figure S.1.4. HMBC spectrum of compound 1(CDCl₃)
- Figure S.1.5. Mass spectrum of compound 1
- Figure S.1.6. IR spectrum of compound 1
- Figure S.1.7. UV spectrum of compound 1
- Figure S.1.8. CD spectrum of compound 1
- Figure S.2.1. ¹H NMR spectrum of compound 2 (400 MHz, CDCl₃)
- Figure S.2.2. ¹³C NMR spectrum of compound 2 (100 MHz, CDCl₃)
- Figure S.2.3. HSQC spectrum of compound 2 (CDCl₃)
- Figure S.2.4. HMBC spectrum of compound 2(CDCl₃)
- Figure S.2.5. Mass spectrum of compound 2
- Figure S.2.6. IR spectrum of compound 2

Figure S.2.7. UV spectrum of compound 2

Figure S.2.8. CD spectrum of compound 2

Figure S.3.1. ¹H NMR spectrum of compound 3 (400 MHz, CDCl₃)

Figure S.3.2. ¹³C NMR spectrum of compound 3 (100 MHz, CDCl₃)

Figure S.3.3. HSQC spectrum of compound 3 (CDCl₃)

Figure S.3.4. HMBC spectrum of compound 3(CDCl₃)

Figure S.3.5. Mass spectrum of compound 3

Figure S.3.6. IR spectrum of compound 3

Figure S.3.7. UV spectrum of compound 3

Figure S.3.8. CD spectrum of compound 3

Tables

Table S.1.

Table S. 2.



Figure S.1.1 ¹H NMR spectrum of compound 1 (400 MHz, CDCl₃)



Figure S.1.2. ¹³C NMR spectrum of compound 1 (100 MHz, CDCl₃)



Figure S.1.3. HSQC spectrum of compound 1 (CDCl₃)

Alvarez id



Figure S.1.4. HMBC spectrum of compound 1(CDCl₃).



Figure S.1.5. Mass spectrum of compound 1.



Figure S.1.6. IR spectrum of compound 1.



Figure S.1.7. UV spectrum of compound 1



Figure S.1.8. CD spectrum of compound 1



File: /home/walkup/vnmrsys/data/ene-feb-14/Alvarez/AcPdx-1H.fid

Pulse Sequence: s2pul



Figure S.2.1. ¹H NMR spectrum of compound 2 (400 MHz, CDCl₃)



File: exp Pulse Sequence: s2pul



Figure S.2.2. ¹³C NMR spectrum of compound 2 (100 MHz, CDCl₃).



Figure S.2.3. HSQC spectrum of compound 2 (CDCl₃).



Figure S.2.4. HMBC spectrum of compound 2(CDCl₃)



Figure S.2.5. Mass spectrum of compound 2.



Figure S.2.6. IR spectrum of compound 2.



Figure S.2.7. UV spectrum of compound 2.



Figure S.2.8. CD spectrum of compound 2.



Figure S.3.1. ¹H NMR spectrum of compound **3** (400 MHz, CDCl₃)

1H BF1.4 CDC13 400MHz Alvarez 17-02-12

Pulse Sequence: s2pul



Figure S.3.2. ¹³C NMR spectrum of compound **3** (100 MHz, CDCl₃)



Figure S.3.3. HSQC spectrum of compound 3 (CDCl₃).

Alvarez id



Figure S.3.4. HMBC spectrum of compound 3(CDCl₃)



Figure S.3.5. Mass spectrum of compound 3

Treatment	Cell cycle activity	H3S10ph fold change		p<0.001	n	Ν	Student´s t-test	
DMSO		1.00	±	0.13		10	1	
Aphidicolin	-	0.23	±	0.05	*	9	1	7.53E-12
Nocodazole	+	1.80	±	0.20	*	9	1	9.81E-09
1	+	1.92	±	0.23	*	10	1	2.41E-09
2	+	2.41	±	0.19	*	10	1	1.73E-13
3	+	2.57	±	0.26	*	10	1	1.88E-12

Table S.1. Quantification of the effect of *B. fagaroides* lignans **1-3** on the cell cycle in zebrafish embryos.

Cell cycle activity; -, denotes decrease, +, increase.

Treatment	Effect on morphology	Circularity			p<0.001	n	Ν	Student´s t-test
DMSO		0.42	±	0.02		10	1	
Aphidicolin	=	0.38	±	0.05		9	1	4.90E-02
Nocodazole	+	0.76	±	0.06	*	9	1	4.80E-12
1	+	0.78	±	0.07	*	10	1	3.10E-12
2	+	0.73	±	0.06	*	10	1	2.56E-11
3	+	0.77	±	0.04	*	10	1	1.68E-15

Table S.2. Quantification of the effect of *B. fagaroides* lignans 1-3 on the morphology of zebrafish embryos.

Circularity, measured circularity. Morphological effect; +, increase in circularity, = without change. n, total number of embryos analyzed. Student's t-test was used to determine the p-value. 1 (7',8'-dehydropodophyllotoxin). 2, (7',8'-dehydro acetyl podophyllotoxin). 3 (7',8'-dehydro-*trans*-p-coumaroyl podophyllotoxin).